Chronic Lymphocytic Leukemia News

Chronic Lymphocytic Leukemia News

Three-Year Follow-Up Supports Fixed-Course Treatment With Obinutuzumab/Ibrutinib-Based Therapy in Treatment-Naive CLL

Publish Date November 19, 2020

Most patients with previously untreated CLL experienced a persistent MRD benefit with a fixed-dose, obinutuzumab-ibrutinib–based treatment approach.

Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions

Publish Date November 12, 2020

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.

Reliability of Laboratory-Developed Tests Called Into Question

Publish Date October 16, 2020

A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.

Fixed-Duration Venetoclax Plus Rituximab Confers Benefit in Chronic Lymphocytic Leukemia

Publish Date October 14, 2020

Fixed-duration venetoclax plus rituximab provides sustained, durable response for patients with relapsed chronic lymphocytic leukemia.

Combined Venetoclax, Obinutuzumab vs Chlorambucil, Obinutuzumab for Chronic Lymphocytic Leukemia

Publish Date October 1, 2020

Venetoclax plus obinutuzumab appears to yield good responses for a limited duration among patients with previously untreated CLL.

How the Coronavirus Pandemic May Affect Cancer Clinical Trials

Publish Date September 23, 2020

Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.

Triple Therapy for CLL Shows Promise in Phase 2 Trial

Publish Date September 21, 2020

Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.

Uncommon Mutation in CLL Associated With More Favorable Prognostic Factors

Publish Date September 16, 2020

Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who had an L265P MYD88 mutation were uncommon and had distinct features.

Risk-Adapted Bendamustine and Rituximab: An Alternative for Older Individuals With CLL

Publish Date September 15, 2020

Risk-adapted dosing of bendamustine and rituximab may be beneficial and tolerable for elderly patients with CLL, a retrospective study found.

Targeted Molecular Therapies for the Treatment of Chronic Lymphocytic Leukemia

Publish Date September 10, 2020

Researchers reviewed promising advances in therapy options for patients with CLL and the challenges associated with these new treatments.

Prior Use of Novel Agents Does Not Affect alloHCT Outcomes in CLL

Publish Date September 1, 2020

Prior treatment with at least 1 novel agent did not affect allogeneic transplant outcomes among patients with CLL.

Can Culturing CAR T Cells With Ibrutinib Improve Their Efficacy in CLL?

Publish Date August 31, 2020

Sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.

CLL Diagnosis Preceded by Decades of Increased Infection Susceptibility

Publish Date August 28, 2020

Infections often precede a formal diagnosis of CLL. Researchers found that antimicrobial use began to rise 6 years prior to CLL diagnosis.

Prior History of SCC Could Be a Red Flag for Development of SCC in the Setting of CLL

Publish Date August 27, 2020

In this study, a cohort of patients with newly diagnosed CLL was followed to identify the incidence of SCC skin cancer and its associated risk factors in this population.

Real-World Data Show Temporal Trends in Risk of Serious Bacterial Infections in Patients With CLL

Publish Date August 13, 2020

These study findings show the risk and incidence of serious bacterial infection and its effect on mortality for patients with CLL.

The Twitter Effect on How Oncologists Conduct and Share Research

Publish Date August 12, 2020

The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.

How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials

Publish Date August 7, 2020

It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.

Identifying Risk Factors for Invasive Fungal Infection in Ibrutinib-Treated CLL Patients

Publish Date July 30, 2020

Ibrutinib-mediated macrophage inhibition may underlie an increased risk of invasive fungal infection in patients with CLL treated with this agent.

Genetic Prognostic Factors in CLL Treated With Novel Compounds

Publish Date July 27, 2020

Obinutuzumab plus venetoclax was associated with improved outcomes compared with obinutuzumab plus chlorambucil, regardless of the presence of unfavorable genetic prognostic factors.

Researchers Reveal Racial Disparities in Access to Remdesivir for Patients With Cancer and COVID-19

Publish Date July 24, 2020

Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.